We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Shellfish Exoskeletons May Reduce Radiation Poisoning

By HospiMedica staff writers
Posted on 03 Oct 2006
An investigator is currently is investigating a novel approach based on a readily available biomaterial that could potentially be used to reduce an individual's radiation dose.

At present, there are no effective methods to isolate and remove radionuclides from humans in the event of a detonation of a suitcase-sized nuclear bomb by a terrorist in a major city. More...
Dr. Tatiana Levitskaia, a scientist from Pacific Northwest National Laboratory (Richmond, WA, USA), reported on the technology at the U.S. national meeting of the American Chemical Society, held in September 2006 in San Francisco (CA, USA).

Chitosan is a natural and safe compound that has been found to be an effective chelator for a wide range of nuclides. Chitosan is obtained from chitin and found in the exoskeletons of many invertebrates such as crabs and prawns. It is one of the most abundant, readily available, and renewable natural biopolymers, second only to cellulose.

Some chitosan materials can be chemically engineered to improve their affinity to specific radionuclides. By binding to radionuclides, scientists hypothesize that chitosan may inhibit deposition in bones and vital organs such as the liver and kidney, and speed up removal from the body.

Dr. Levitskaia's investigation is targeted at finding a natural chelator such as chitosan that can safely and effectively rid the body of diverse radionuclides such as actinides, cobalt, strontium, and radium. Currently, Dr. Levitskaia's research involves the removal of cobalt from living tissues in laboratory rats. Results are expected in the fall of 2006.



Related Links:
Pacific Northwest National Laboratory

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Patient Monitoring System
AlarmSense
New
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The nasal spray is created using the ‘Nano-in-Micron’ technology platform. The micron-sized powder is inhaled and travels along the nose-to-brain pathway, bypassing the blood-brain barrier to deliver the drug directly to the brain (Photo courtesy of The University of Hong Kong

New Nasal Spray Enables Prehospital Neuroprotection in Ischemic Stroke

Ischemic stroke, caused by arterial occlusion in the brain, requires time‑critical intervention to limit neuronal loss. Many patients arrive outside the narrow window for thrombolysis or thrombectomy,... Read more

Surgical Techniques

view channel
Image

New Endoscopic Device Offers Minimally Invasive Approach to Obesity Management

Obesity is increasing worldwide, and many patients face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.